Compound: gemfibrozil
SMILES: O=C(O)C(CCCOc1c(ccc(c1)C)C)(C)C
InChIKey: HEMJJKBWTPKOJG-UHFFFAOYSA-N
Synonyms: gemfibrozil, 25812-30-0, 5-(2,5-Dimethylphenoxy)-2,2-dimethylpentanoic acid, Lopid, Jezil, Lipur, CI-719, Gemfibrozilo, Gemlipid, Gemfibrozilum, Gen-Fibro, Pentanoic acid, 5-(2,5-dimethylphenoxy)-2,2-dimethyl-, 2,2-Dimethyl-5-(2,5-xylyloxy)valeric acid, 2,2-Dimethyl-5-(2,5-xylyloxy)valeriansaeure, CI 719, 2,2-Dimethyl-5-(2,5-dimethylphenoxy)valeriansaeure, DTXSID0020652, NSC-757024, Valeric acid, 2,2-dimethyl-5-(2,5-xylyloxy)-, Gemfibrosil, Q8X02027X3, DTXCID20652, CHEBI:5296, Lopid R, ApoGemfibrozil, GenGemfibrozil, Genlip, NuGemfibrozil, Apo Gemfibrozil, Gen Gemfibrozil, Nu Gemfibrozil, Novo Gemfibrozil, PMS Gemfibrozil, Gemfibrozil, SBPA, Gemfibrozil, GenRX, Bayvit, Gemfibrozilo, Gemfibrozil, Healthsense, CI719, Emfib, RefChem:57800, C10AB04, 247-280-2, 657-339-8, Decrelip, MFCD00079335, Gemfibrozil (Lopid), Bolutol, Apo-Gemfibrozil, Gemfibrozil (Standard), Cholespid, Gemfibril, Gemfibromax, Fibratol, Fibrocit, Lipazil, Litarek, Trialmin, Ausgem, Pilder, CHEMBL457, 2,2-Dimethyl-5-(2,5-dimethylphenoxy)pentanoic acid, MLS000028421, Renabrazin, Clearol, Elmogan, Fetinor, Gemnpid, Innogen, Ipolipid, Lanaterom, Lifibron, Lipigem, Lipizyl, Lipozid, Micolip, Normolip, Progemzal, Reducel, Regulip, Sinelip, Synbrozil, Taborcil, Tentroc, Brozil, Lipira, Gozid, Hidil, Gemd, WL-Gemfibrozil, Gevilon Uno, Low-Lip, 5-(2,5-dimethylphenoxy)-2,2-dimethyl-pentanoic acid, 5-[(2,5-dimethylphenyl)oxy]-2,2-dimethylpentanoic acid, Gem-S, NCGC00016794-09, SMR000058393, CAS-25812-30-0, Gemfibrozilum [INN-Latin], Gemfibrozilo [INN-Spanish], Organolipid, Innogem, Gemcor, CCRIS 318, Lopid (TN), TEVA-A, SR-01000000056, EINECS 247-280-2, BRN 1881200, Gemfibrozil (JAN/USP/INN), Hipolixan;, Gemfibrozil CRS, Lipozid;, Gemcor;, UNII-Q8X02027X3, HSDB 7735, Emfib;, Lipur;, Lopid;, 4TX, Gemfibrozil [USAN:USP:INN:BAN], Prestwick_637, Spectrum_000825, CPD000058393, GEMFIBROZIL [MI], 114413-98-8, Opera_ID_1658, Prestwick0_000214, Prestwick1_000214, Prestwick2_000214, Prestwick3_000214, Spectrum2_001097, Spectrum3_000440, Spectrum4_000562, Spectrum5_000750, Spectrum5_001991, GEMFIBROZIL [INN], GEMFIBROZIL [JAN], GEMFIBROZIL [HSDB], GEMFIBROZIL [IARC], GEMFIBROZIL [USAN], GEMFIBROZIL [VANDF], SCHEMBL4813, GEMFIBROZIL [MART.], BSPBio_000227, BSPBio_002060, GEMFIBROZIL [USP-RS], GEMFIBROZIL [WHO-DD], KBioGR_000964, KBioSS_001305, 2,2-Dimethyl-5-(2,5-dimethylphenoxy)valeric Acid, MLS001055364, MLS006011850, DivK1c_000138, SPECTRUM1500313, SPBio_001174, SPBio_002148, BPBio1_000251, CI-7, GTPL3439, orb1308681, orb3025505, SCHEMBL9481043, Gemfibrozil, analytical standard, SCHEMBL29398115, HMS500G20, HY-B0258R, KBio1_000138, KBio2_001305, KBio2_003873, KBio2_006441, KBio3_001280, GEMFIBROZIL [ORANGE BOOK], Gemfibrozil for system suitability, NINDS_000138, GEMFIBROZIL [EP MONOGRAPH], GLXC-07494, HMS1568L09, HMS1920B07, HMS2090K14, HMS2091H11, HMS2095L09, HMS2230H24, HMS3259M12, HMS3655C06, HMS3712L09, HMS5079L18, Pharmakon1600-10500313, GEMFIBROZIL [USP MONOGRAPH], HY-B0258, MSK10081, Tox21_110613, Tox21_201997, Tox21_302784, BBL010807, BDBM50110590, CCG-40111, DL-414, EBC-06088, NSC757024, s1729, SBB012457, STK618740, AKOS001606691, Gemfibrozil for system suitability CRS, Tox21_110613_1, AB03034, AC-4225, DB01241, FD23652, KS-5192, NC00565, NSC 757024, IDI1_000138, NCGC00016794-01, NCGC00016794-02, NCGC00016794-03, NCGC00016794-04, NCGC00016794-05, NCGC00016794-06, NCGC00016794-07, NCGC00016794-08, NCGC00016794-10, NCGC00016794-11, NCGC00016794-13, NCGC00016794-14, NCGC00022722-03, NCGC00022722-04, NCGC00022722-05, NCGC00022722-06, NCGC00022722-07, NCGC00256601-01, NCGC00259546-01, ST072198, SY052512, Gemfibrozil 100 microg/mL in Acetonitrile, SBI-0051391.P003, AB00052003, CS-0694895, G0368, NS00010281, SW196802-3, EN300-97098, C07020, D00334, D83091, AB00052003-15, AB00052003-16, AB00052003_17, AB00052003_18, F054267, Q384295, SR-01000000056-3, SR-01000000056-4, SR-01000000056-6, SR-01000000056-7, 2,2-Dimethyl-5-(2,5-dimethylphenoxy)-pentanoic acid, 2,2-DIMETHYL-5-(2,5-XYLYLOXY) VALERIC ACID, BRD-K11129031-001-05-1, BRD-K11129031-001-26-7, BRD-K11129031-001-27-5, Z1259021151, Gemfibrozil, British Pharmacopoeia (BP) Reference Standard, Gemfibrozil, European Pharmacopoeia (EP) Reference Standard, Gemfibrozil, United States Pharmacopeia (USP) Reference Standard, Gemfibrozil, Pharmaceutical Secondary Standard; Certified Reference Material, Gemfibrozil for system suitability, European Pharmacopoeia (EP) Reference Standard, 2,2-Dimethyl-5-(2,5-dimethylphenoxy)pentanoic acid, 2,2-Dimethyl-5-(2,5-xylyloxy)valeric acid, 5-(2,5-Dimethylphenoxy)-2,2-dimethylpentanoic aci
Theoretical properties:
molecular_formula: C15H22O3
molecular_weight: 250.33 g/mol
exact_mass: 250.15689456 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 1
hydrogen_bond_acceptor_count: 3
rotatable_bond_count: 6
heavy_atom_count: 18
topological_polar_surface_area: 46.5 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
physical_state: Crystals from hexane
color: Crystals from hexane
melting_point: 58-61
solubility: 2.78e-02 g/L
Descriptions:
pubchem: Gemfibrozil can cause cancer, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements.
chembl: GEMFIBROZIL is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Gemfibrozil, sold under the brand name Lopid among others, is a medication used to treat abnormal blood lipid levels. It is generally less preferred than statins. Use is recommended together with dietary changes and exercise. It is unclear if it changes the risk of heart disease. It is taken by mouth.
Common side effects include headache, dizziness, feeling tired, and intestinal upset. Serious side effects may include angioedema, gallstones, liver problems, and muscle breakdown. Use in pregnancy and breastfeeding is of unclear safety. It belongs to the fibrates group of medications and works by decreasing the breakdown of lipids in fat cells.
Gemfibrozil was patented in 1968, and came into medical use in 1982. It is available as a generic medication. In 2022, it was the 231st most commonly prescribed medication in the United States, with more than 1 million prescriptions.